Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

Cancer letters - 1 Jun 2021

Lee Ji Eun, Kang Yeo Wool, Jung Kyung Hee, Son Mi Kwon, Shin Seung-Min, Kim Ji-Sun, Kim Soo Jung, Fang Zhenghuan, Yan Hong Hua, Park Jung Hee, Yoon Young-Chan, Han Boreum, Cheon Min Ji, Woo Min Gyu, Seo Myung Sung, Lim Joo Han, Kim Yong-Sung, Hong Soon-Sun

Abstract excerpt

KRAS mutation is associated with the progression and growth of pancreatic cancer and contributes to chemo-resistance, which poses a significant clinical challenge in pancreatic cancer. Here, we developed a RT22-ep59 antibody (Ab) that directly targets the intracellularly activated GTP-bound form of oncogenic KRAS mutants after it is internalized into cytosol by endocytosis through tumor-associated receptor of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Synergism

Share to Endosomes

Share to Epithelial Cell Adhesion Molecule

Share to Gemcitabine

Share to Tumor Burden

Source

Identifiers

PMID: 33744388
DOI: 10.1016/j.canlet.2021.03.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.PMID 33744388Read ↗

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.Semantic proximity Read ↗

Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers.Semantic proximity Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.Semantic proximity Read ↗

EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo.Semantic proximity Read ↗

Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation.Semantic proximity Read ↗

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.Semantic proximity Read ↗

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.Semantic proximity Read ↗

Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.Semantic proximity Read ↗

Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells.Semantic proximity Read ↗

Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.Semantic proximity Read ↗

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.